TIFA anticorps (AA 51-150) (Biotin)

N° du produit ABIN1700078

L’anticorps Lapin Polyclonal anti-TIFA a été validé pour ELISA, WB, IHC (fro) et IHC (p). Il convient pour détecter TIFA dans des échantillons de Souris.

Aperçu rapide pour TIFA anticorps (AA 51-150) (Biotin) (ABIN1700078)

Antigène: TIFA (TRAF-Interacting Protein with Forkhead-Associated Domain (TIFA))

Reactivité: Souris

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp TIFA est conjugé à/à la Biotin

Application: ELISA, Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Détail du produit anti-TIFA anticorps (Biotin)

Épitope: AA 51-150

Réactivité croisée: Souris

Homologie: Human,Rat,Dog,Cow,Sheep,Pig,Chicken

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic peptide derived from human TIFA

Isotype: IgG

Information d'application

Indications d'application: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: ProClin

Précaution d'utilisation: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C for 12 months.

Date de péremption: 12 months

Détails sur TIFA

Antigène: TIFA (TRAF-Interacting Protein with Forkhead-Associated Domain (TIFA))

Autre désignation: TIFA

Sujet:

Synonyms: Putative MAPK activating protein PM14, Putative MAPK-activating protein PM14, Putative NF kappa B activating protein 20, Putative NF-kappa-B-activating protein 20, T2BP, TA, TA_HUMAN, TRAF interacting protein with FHA domain containing protein A, TRAF-interacting protein with FHA domain-containing protein A, TRAF2 binding protein, TRAF2-binding protein.

Background: Adapter protein which mediates the IRAK1 and TRAF6 interaction following IL-1 stimulation, resulting in the downstream activation of NF-kappa-B and AP-1 pathways. Induces the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism.